HIGHLIGHTS
- who: Third Vaccine - Kidney et al. from the (UNIVERSITY) have published the Article: Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients u2014 A Prospective Study, in the Journal: (JOURNAL)
- what: The authors aimed to evaluate humoral and cellular response specifically among KTRs ~3 weeks after a third dose of BNT162b2 vaccine dose in Israel. Immunosuppression reduction was not planned for the study and was initiated by either patients or treating physicians, due to reasons related or unrelated to the vaccine.
- how: Were compared with a control group of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.